View : 114 Download: 0

Diagnostic yield of contrast-enhanced abdominal staging CT in patients with initially diagnosed breast cancer

Title
Diagnostic yield of contrast-enhanced abdominal staging CT in patients with initially diagnosed breast cancer
Authors
LeeYoung-WonBoryeongSae ByulKimJisunChungIl YongHee JeongKoBeom SeokJong WonSonByung HoGwarkSungchanShinHee JungYooTae-KyungChoiSang HyunJeong
Ewha Authors
곽성찬
SCOPUS Author ID
곽성찬scopus
Issue Date
2024
Journal Title
European Journal of Radiology
ISSN
0720-048XJCR Link
Citation
European Journal of Radiology vol. 171
Keywords
Breast neoplasmsLiverMultidetector computed tomographyNeoplasm metastasisNeoplasm staging
Publisher
Elsevier Ireland Ltd
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Purpose: To estimate the diagnostic yield (DY) of abdominal staging CT for detecting breast cancer liver metastasis (BCLM) in patients with initially diagnosed breast cancer and to determine the indications for abdominal staging CT. Methods: Patients with newly diagnosed breast cancer who underwent abdominal CT as an initial staging work-up between January 2019 and December 2020 were retrospectively analyzed. DY was calculated and analyzed according to patient age, type of treatments, histologic type, histologic grade, lymphovascular invasion, Ki-67 status, hormone receptor status, subtype, and the American Joint Committee on Cancer anatomical staging. Results: A total of 2056 patients (mean age, 51 ± 11 years) were included. The DY of abdominal staging CT for detecting BCLM was 1.1 % (22 of 2056). DY was significantly higher in stage III than in stage I or II cancers (3.9 % [18 of 467] vs. 0 % [0 of 412] or 0.4 % [4 of 1158], respectively, p < .001), and in human epidermal growth factor receptor-2 (HER2)-enriched cancers than in luminal or triple negative cancers (2.9 % [16 of 560] vs. 0.4 % [4 of 1090] or 0.5 % [2 of 406], respectively, p < .001). Conclusions: The DY of abdominal staging CT for detecting BCLM was low among all patients with initially diagnosed breast cancer. However, although abdominal staging CT for detecting BCLM is probably unnecessary in all patients, it can be clinically useful in patients with stage III or human epidermal growth factor receptor-2-enriched breast cancers. © 2024 Elsevier B.V.
DOI
10.1016/j.ejrad.2024.111295
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE